接受免疫检查点抑制剂治疗的癌症患者发生内分泌并发症的风险：一项荟萃分析。

Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.

作者信息

Abdel-Rahman Omar, ElHalawani Hesham, Fouad Mona

机构信息

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

出版信息

Future Oncol. 2016 Feb;12(3):413-25. doi: 10.2217/fon.15.222. Epub 2016 Jan 18.

DOI:10.2217/fon.15.222

PMID:26775673

Abstract

BACKGROUND

We performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors.

METHODS

Eligible studies included randomized trials of cancer patients on immune checkpoint inhibitors; describing events of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency.

RESULTS

A total of ten clinical trials were eligible for the meta-analysis. The relative risk of all-grade hypothyroidism, hyperthyroidism, hypophyisitis and adrenal insufficiency were 8.26 (95% CI: 4.67-14.62; p < 0.00001), 5.48 (95% CI: 1.33-22.53; p = 0.02); 22.03 (95% CI: 8.52-56.94; p < 0.00001), 3.87 (95% CI: 1.12-13.41; p = 0.03), respectively.

CONCLUSION

Our meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.

摘要

背景

我们对与免疫检查点抑制剂相关的内分泌不良事件风险进行了一项荟萃分析。

方法

符合条件的研究包括癌症患者使用免疫检查点抑制剂的随机试验；描述甲状腺功能减退、甲状腺功能亢进、垂体炎和肾上腺功能不全的事件。

结果

共有10项临床试验符合荟萃分析的条件。所有级别甲状腺功能减退、甲状腺功能亢进、垂体炎和肾上腺功能不全的相对风险分别为8.26（95%置信区间：4.67 - 14.62；p < 0.00001）、5.48（95%置信区间：1.33 - 22.53；p = 0.02）、22.03（95%置信区间：8.52 - 56.94；p < 0.00001）、3.87（95%置信区间：1.12 - 13.41；p = 0.03）。